Holman Ryan, McDannold Nathan
Focused Ultrasound Laboratory, Department of Radiology, Brigham and Women's Hospital, Boston, MA, United States.
Front Oncol. 2025 Mar 13;15:1507940. doi: 10.3389/fonc.2025.1507940. eCollection 2025.
Glioblastoma, a grade IV astrocytoma, typically has a poor prognosis, with most patients succumbing within eighteen months of diagnosis and few experiencing long-term survival. Focused ultrasound, an emerging localized therapy, has shown promising results in early-phase studies for glioblastoma by improving the uptake of temozolomide and carboplatin. The blood-brain barrier is critical to homeostasis by regulating the movement of substances between the bloodstream and the central nervous system. While this barrier helps prevent infections from bloodborne pathogens, it also hinders the delivery of cancer therapies to gliomas. Combining focused ultrasound with circulating microbubbles enhances local blood-brain barrier permeability, facilitating the intratumoral uptake of systemic cancer therapies. The purpose of this study was to identify promising new therapeutics in the treatment of glioblastoma for localized drug delivery via focused ultrasound. This review provides an overview of the current standard of care for newly diagnosed and recurrent glioblastoma, identifies current therapies indicated for the treatment, discusses key aspects of microbubble resonators, describes focused ultrasound devices under evaluation in human trials, and concludes with a perspective of emerging therapeutics for future studies.
胶质母细胞瘤是一种IV级星形细胞瘤，通常预后较差，大多数患者在诊断后18个月内死亡，很少有患者能长期存活。聚焦超声是一种新兴的局部治疗方法，在胶质母细胞瘤的早期研究中已显示出有前景的结果，它能提高替莫唑胺和卡铂的摄取。血脑屏障通过调节血液与中枢神经系统之间物质的移动对体内平衡至关重要。虽然这种屏障有助于防止血源性病原体感染，但它也阻碍了癌症治疗药物向胶质瘤的递送。将聚焦超声与循环微泡相结合可增强局部血脑屏障的通透性，促进全身癌症治疗药物在肿瘤内的摄取。本研究的目的是确定通过聚焦超声进行局部药物递送治疗胶质母细胞瘤的有前景的新疗法。本综述概述了新诊断和复发性胶质母细胞瘤的当前护理标准，确定了目前用于治疗的疗法，讨论了微泡谐振器的关键方面，描述了正在人体试验中评估的聚焦超声设备，并以对未来研究的新兴疗法的展望作为结论。
